119 related articles for article (PubMed ID: 8690814)
1. Pharmacokinetics of ondansetron in patients with hepatic insufficiency.
Figg WD; Dukes GE; Pritchard JF; Hermann DJ; Lesesne HR; Carson SW; Songer SS; Powell JR; Hak LJ
J Clin Pharmacol; 1996 Mar; 36(3):206-15. PubMed ID: 8690814
[TBL] [Abstract][Full Text] [Related]
2. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.
Blake JC; Palmer JL; Minton NA; Burroughs AK
Br J Clin Pharmacol; 1993 Apr; 35(4):441-3. PubMed ID: 8485026
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
[TBL] [Abstract][Full Text] [Related]
5. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.
Yang SH; Lee MG
Biopharm Drug Dispos; 2008 Oct; 29(7):414-26. PubMed ID: 18697186
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron clinical pharmacokinetics.
Roila F; Del Favero A
Clin Pharmacokinet; 1995 Aug; 29(2):95-109. PubMed ID: 7586904
[TBL] [Abstract][Full Text] [Related]
7. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
[TBL] [Abstract][Full Text] [Related]
8. Gender differences in ondansetron pharmacokinetics in rats.
Yang SH; Yang KH; Lee MG
Biopharm Drug Dispos; 2008 Oct; 29(7):406-13. PubMed ID: 18696412
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
10. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction.
Stubbs K; Martin LA; Dimmitt DC; Pready N; Hahne WF
J Clin Pharmacol; 1997 Oct; 37(10):926-36. PubMed ID: 9505984
[TBL] [Abstract][Full Text] [Related]
12. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Branch RA; James JA; Read AE
Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
14. The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor.
Sarapa N; Britto MR; Mainka MB; Parivar K
Eur J Clin Pharmacol; 2005 Jun; 61(4):247-56. PubMed ID: 15887009
[TBL] [Abstract][Full Text] [Related]
15. Ondansetron metabolism and pharmacokinetics.
Pritchard JF
Semin Oncol; 1992 Aug; 19(4 Suppl 10):9-15. PubMed ID: 1387254
[TBL] [Abstract][Full Text] [Related]
16. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
Villikka K; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.
Hoover R; Marbury TC; Preston RA; Quintas M; Lawrence LE; Paulson SK; Luke DR; Cammarata SK
J Clin Pharmacol; 2017 Mar; 57(3):328-335. PubMed ID: 27570245
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of conivaptan use in patients with severe hepatic impairment.
Marbury T; Fox J; Kaelin B; Pavliv L
Drug Des Devel Ther; 2017; 11():373-382. PubMed ID: 28243060
[TBL] [Abstract][Full Text] [Related]
19. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
20. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
